Journal of the Neurological Sciences
Volume 211, Issue 1 , Pages 81-84 , 15 July 2003

Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients

Received 19 July 2002 ,Revised 12 February 2003 ,Accepted 13 February 2003.

References 

  1. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al.  Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–178
  2. Rohrbach E, Kappos L, Städt D, Kaiser D, Hennes A, Dommasch D, et al.  Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial. Neurology. 1988;38(Suppl. 1):256
  3. Heun R, Sliwka U, Ruttinger H, Schimrigk K. Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study. J. Neurol. 1992;239(1):31–35
  4. Nelson DA, Landau WM. Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J. Neurol. Neurosurg. Psychiatry. 2001;70(4):433–443
  5. Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M, et al.  Intrathecal methylprednisolone for intractable postherpetic neuralgia. N. Engl. J. Med. 2000;343(21):1514–1519
  6. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13(3):227–231
  7. Braune HJ, Huffmann GA. A prospective double-blind clinical trial, comparing the sharp Quincke needle (22G) with an “atraumatic” needle (22G) in the induction of post-lumbar puncture headache. Acta Neurol. Scand. 1992;86(1):50–54
  8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452
  9. Neu I, Reusche E, Rodiek S. Endogenous cortisol levels after intrathecal injection of triamicinolone acetonide in patients with neurological disease. Dtsch. Med. Wochenschr. 1978;103(35):1368–1370 [author's transl]
  10. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, et al.  A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology. 1998;51(1):239–245
  11. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, et al.  Effects of IV methylprednisolone on brain atrophy in relapsing–remitting MS. Neurology. 2001;57(7):1239–1247

PII: S0022-510X(03)00060-1

doi: 10.1016/S0022-510X(03)00060-1

Journal of the Neurological Sciences
Volume 211, Issue 1 , Pages 81-84 , 15 July 2003

Article Tools